Shots:

• Eli Lilly shared new results from a subgroup analysis of the P-IIIb/IV- 52-wks. SPIRIT-H2H study assessing Taltz vs Humira (adalimumab) in biologic-naïve patients with active PsA with 1EPs as ACR50 & PASI 100 @24wks. The study compares Taltz and Humira in subgroups of patients on monothx./ concomitant MTX/ concomitant MTX along with csDMARD including sulfasalazine- cyclosporine- or leflunomide
•  Results: MDA (49% vs 33%)/ (47% vs 47%)/ (47% vs 44%); 1EPs @52wks.(38% vs 19%) (39% vs 30%) (40% vs 29%); PASI 100 (66% vs 35%)/ (63% vs 44%)/ (64% vs 44%); ACR50 (51% vs 42%)/ (48% vs 56%)/ (49% vs 53%) respectively- data will be presented at EULAR on Jun 05- 2020. The safety profile for Taltz was consistent with knows safety of the therapy in patients with moderate to severe PsO and PsA
• Lilly also highlights results from two additional study SPIRIT-P2 study and P-III COAST-X study. The SPIRIT-P2 study demonstrated sustained improvement in signs and symptoms of PsA and P-III COAST-X study showed improvement in fatigue- spinal pain and stiffness @16wks.in patients with active nr-axSpA

Click here to read full press release/ article 

Ref: Eli Lilly | Image: Eli Lilly